Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
Status:
Withdrawn
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and effectiveness of three doses of
intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration
following initiation of anti-VEGF therapy with three doses of Lucentis®.